<SEC-DOCUMENT>0001628280-25-036846.txt : 20250731
<SEC-HEADER>0001628280-25-036846.hdr.sgml : 20250731
<ACCEPTANCE-DATETIME>20250731073617
ACCESSION NUMBER:		0001628280-25-036846
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250729
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250731
DATE AS OF CHANGE:		20250731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRESCENT BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		251169449

	BUSINESS ADDRESS:	
		STREET 1:		300 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-430-5595

	MAIL ADDRESS:	
		STREET 1:		300 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLYCOMIMETICS INC
		DATE OF NAME CHANGE:	20030711
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cbio-20250729.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:77c2f864-6fb7-459c-9e5f-aaeb1b69cd1d,g:111b592c-dd60-41d3-86a7-d658a669c678,d:5ab61d66f4be4b26a0d1804e5505467e-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cbio-20250729</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001253689</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cbio-20250729.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-29</xbrli:startDate><xbrli:endDate>2025-07-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5ab61d66f4be4b26a0d1804e5505467e_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">July 29, 2025</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Crescent Biopharma, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Charter)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-4">Cayman Islands</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36177</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">06-1686563</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">300 Fifth Avenue</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">02451</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">430-5595</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________________________________________________</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2. below):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.416%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Ordinary Shares, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CBIO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">o</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div><div id="i5ab61d66f4be4b26a0d1804e5505467e_4"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2025, Crescent Biopharma, Inc. (the &#8220;Company&#8221;) issued a press release announcing the Company&#8217;s financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 and Exhibits 99.1 attached hereto is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.</span></div><div id="i5ab61d66f4be4b26a0d1804e5505467e_88"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.02</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2025, the Board of Directors of the Company approved the Crescent Biopharma, Inc. Executive Severance Plan (the &#8220;Severance Plan&#8221;), which provides severance benefits to employees who hold the title of Vice President or higher, including each of the Company&#8217;s executive officers (the &#8220;participants&#8221;), in the event of a participant&#8217;s termination of employment without Cause or resignation for Good Reason, each as defined in the Severance Plan (a &#8220;Qualifying Termination&#8221;) and enhanced severance benefits if such termination occurs within three months before to 12 months after a Change in Control (as defined in the Severance Plan) of the Company (a &#8220;CIC Qualifying Termination&#8221;). The severance benefits provided in the Severance Plan supersede the separation benefits, if any, provided under the terms of each participant&#8217;s offer letter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Severance Plan, in the event of a Qualifying Termination, and subject to the participant&#8217;s execution of a general release of claims and continued compliance with all restrictive covenant obligations with the Company, the participant will receive: (i) base salary continuation equal to the participant&#8217;s &#8220;Severance Multiplier&#8221; multiplied by the participant&#8217;s base salary; (ii) Company-subsidized continuation coverage under the Company&#8217;s group health plans for up to a number of months equal to the participant&#8217;s &#8220;COBRA Multiplier&#8221;; and (iii) any other additional benefits specified in the participant&#8217;s participation agreement. In the event of a CIC Qualifying Termination, and subject to the participant&#8217;s execution of a general release of claims and continued compliance with all restrictive covenant obligations with the Company, the participant will receive: (i) a lump sum severance payment equal to the participant&#8217;s &#8220;CIC Severance Multiplier&#8221; multiplied by the sum of the participant&#8217;s base salary plus target bonus; (ii) any unpaid annual bonus for the year immediately preceding the termination year based on actual performance; (iii) a lump sum cash payment equal to the participant&#8217;s &#8220;CIC COBRA Multiplier&#8221; multiplied by the monthly continuation coverage premiums for the participant and the participant&#8217;s covered dependents; and (iv) accelerated vesting of the participant&#8217;s then outstanding equity-based awards, with any performance-based vesting conditions deemed to have been met based on the greater of target or, if determinable, actual performance.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subject to their execution of a participation agreement, (i) the Company&#8217;s Chief Executive Officer will participate in the Severance Plan with a Severance Multiplier of 1.0x, a COBRA Multiplier of 12, a CIC Severance Multiplier of 1.5x, and a CIC COBRA Multiplier of 18, (ii) the Company&#8217;s other executive officers, other than Ryan Lynch, will participate with a Severance Multiplier of 1.0x, a COBRA Multiplier of 12, a CIC Severance Multiplier of 1.25x, and a CIC COBRA Multiplier of 15, and (iii) Mr. Lynch will participate with a Severance Multiplier of 0.75x, a COBRA Multiplier of 9, a CIC Severance Multiplier of 1.0x, and a CIC COBRA Multiplier of 12. In addition, upon a Qualifying Termination after March 17, 2026, for the Company's Chief Executive Officer and Chief Operating Officer and President, 30% of the unvested portion of their outstanding time-based equity awards will accelerate and become vested. In the event any of the amounts provided under the Severance Plan (or otherwise) would constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and subject to the excise tax imposed by Section 4999 of the Code, then the Company&#8217;s executive officers (other than Mr. Lynch) will be eligible to receive a tax gross-up payment with respect to the excise tax imposed by Section 4999 of the Code. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Severance Plan does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Severance Plan, a copy of which is filed as Exhibit 10.1.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div><div id="i5ab61d66f4be4b26a0d1804e5505467e_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit-101xexecutivesever.htm">Crescent Biopharma, Inc. Executive Severance Plan and Form of Participation Agreement</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="pressrelease-q22025.htm">Press Release issued by Crescent Biopharma, Inc. on July 31, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div><div id="i5ab61d66f4be4b26a0d1804e5505467e_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:24pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">CRESCENT BIOPHARMA, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: July 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Joshua Brumm</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Joshua Brumm</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit-101xexecutivesever.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6b69201f56914b5b8cf6be04810c8cf4_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">CRESCENT BIOPHARMA, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EXECUTIVE SEVERANCE PLAN </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.71pt">Purpose</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. The purpose of the Crescent Biopharma, Inc. Executive Severance Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is to provide severance benefits to certain employees of Crescent Biopharma, Inc. and its Affiliates (as defined below) in the event of a CIC Qualifying Termination or a Qualifying Termination (each as defined below). The Plan is maintained for the purpose of providing benefits for a select group of management or highly compensated employees.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.09pt">Term</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. The Plan will be effective as of July 29, 2025 and remain in effect until terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.71pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any entity in which the Company has a substantial direct or indirect equity interest.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the annual base salary in effect for the Participant immediately before the Participant&#8217;s termination of employment (without giving effect to any reduction that constitutes Good Reason), excluding overtime, bonuses, incentive compensation or any other special payments.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as determined by the Committee, the Participant&#8217;s (i) dishonest statements or acts with respect to the Company or any Affiliate, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company&#59; (ii) conviction or plea of no contest to&#58; (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud&#59; (iii) failure to perform in all material respects their assigned duties and responsibilities, which failure continues for 30 days after written notice given to the Participant describing such failure&#59; (iv) gross negligence or willful misconduct that results in or is reasonably anticipated to result in material harm to the Company&#59; or (v) violation of any material provision of any agreement(s) between the Participant and the Company or any written Company policies, including agreements relating to non-solicitation, non-disclosure or assignment of inventions or policies related to ethics or workplace conduct. A Participant&#8217;s employment will be deemed to have been terminated for Cause if it is determined subsequent to such Participant&#8217;s termination that grounds for a termination for Cause existed at the time of such termination, as determined by the Committee.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Crescent Biopharma, Inc. 2025 Stock Incentive Plan or any successor equity incentive plan adopted by the Company as in effect at the time of determination.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the period beginning three months before and ending 12 months after the consummation of the first event constituting a Change in Control.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">CIC COBRA Multiplier</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the applicable CIC COBRA Multiplier for the Participant&#8217;s Tier as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">CIC Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a termination of the Participant&#8217;s employment with the Company by the Company without Cause (other than by reason of death or Disability) or by the Participant for Good Reason, in each case, during the Change in Control Period. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">CIC Severance Multiplier</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the applicable CIC Severance Multiplier for the Participant&#8217;s Tier as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985 and any guidance and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">COBRA Multiplier</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the applicable COBRA Multiplier for the Participant&#8217;s Tier as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986 and any guidance and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Compensation Committee of the Board or another duly constituted committee of the Board designated by the Board as the Committee hereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Crescent Biopharma, Inc. and its Affiliates (including the Employer), including any successor.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a permanent and total disability as defined in Section 22(e)(3) of the Code.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Crescent Biopharma, Inc., or any other applicable Affiliate that employs a Participant.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">ERISA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Employee Retirement Income Security Act of 1974 and any guidance and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following without the prior consent of the Participant&#58; (i) a material diminution in the Participant&#8217;s base salary or target annual bonus except for across-the-board salary and target bonus reductions of no more than 10% based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company&#59; (ii) a relocation in the Participant&#8217;s principal place of employment by more than 50 miles&#59; (iii) the material breach by the Company of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> or any other agreement between the Participant and the Company&#59; or (iv) for Tier 1 Participants, a material reduction in the Participant&#8217;s duties, authority or responsibilities. Notwithstanding the foregoing, any assertion by the Participant of a termination for Good Reason will not be effective unless&#58; (A) the Participant notifies the Company in writing of the first occurrence of the Good Reason condition within 30 days of the first occurrence of such condition&#59; (B) the Participant cooperates in good faith with the Company&#8217;s efforts, for a period of not less than 30 days following such notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), to remedy the condition&#59; (C) the Good Reason condition continues to exist following the end of the Cure Period&#59; and (D) the Participant terminates the Participant&#8217;s employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason will be deemed not to have occurred.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an employee of the Company who participates in the Plan pursuant to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a termination of the Participant&#8217;s employment with the Company by the Company without Cause (other than by reason of death or Disability) or by the Participant for Good Reason, in each case, outside of the Change in Control Period. If the Participant is primarily providing services to a business unit, as determined by the Committee, which is directly or indirectly sold, licensed or transferred resulting in a termination of the Participant&#8217;s employment with the Company, a Qualifying Termination will not be deemed to occur if upon or within 120 days following the closing of such sale, license or transfer, the Participant (i) accepts any position with the purchaser or any of its affiliates or (ii) is offered employment with the purchaser that does not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#002060;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">require a relocation of the Participant&#8217;s principal place of employment by more than 50 miles and does not result in a material diminution in the Participant&#8217;s base salary or target annual bonus, even if the Participant does not accept such offer of employment.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the severance payments and benefits provided under </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Severance Multiplier</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the applicable Severance Multiplier for the Participant&#8217;s Tier as set forth on </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(w)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.74pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the annual performance bonus in effect for the Participant immediately before the Participant&#8217;s termination of employment (without giving effect to any reduction that constitutes Good Reason) if all applicable performance goals were achieved at 100% of target performance.   </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the date of the Participant&#8217;s termination of employment with the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.09pt">Eligibility</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Unless otherwise determined by the Committee, all employees of the Company who hold the title of Vice President or higher (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Eligible Employees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be eligible to become a Participant, subject to execution of a Participation Agreement with the Company in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. If an employee ceases to hold a position qualifying as an Eligible Employee, then such employee shall no longer be a Participant with no further action required on the part of the Company or such employee, effective as of the date such employee ceases to hold a position qualifying as an Eligible Employee.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.71pt">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Upon a Participant&#8217;s Qualifying Termination, subject to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, such Participant will receive&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">A cash amount equal to the Participant&#8217;s Severance Multiplier times the Participant&#8217;s Base Salary, payable in accordance with the Company&#8217;s regular payroll practices beginning on the Company&#8217;s first regularly scheduled payroll date that is at least 10 days following the date the Release becomes effective and irrevocable&#59; provided, however, that the first installment shall include any amounts that would have been paid following the Termination Date had such installments commenced on the first regularly scheduled payroll date following the Termination Date&#59; provided, further, that if the period during which the Release could become effective and irrevocable spans two calendar years, the first installment shall occur in the second calendar year&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">Subject to the Participant&#8217;s copayment of premium amounts at the applicable active employees&#8217; rate and the Participant&#8217;s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider(s), the COBRA provider, or the Participant a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Participant and the Participant&#8217;s covered dependents&#8217; if the Participant had remained employed by the Company until the earliest of (A) the end of a number of months equal to the Participant&#8217;s COBRA Multiplier&#59; (B) the Participant&#8217;s eligibility for group health plan benefits under any other employer&#8217;s group health plan&#59; or (C) the cessation of Participant&#8217;s continuation rights under COBRA&#59; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Participant for the time period </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#002060;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">specified above on the Company&#8217;s regular payroll dates (subject to tax withholdings as applicable)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">Any other additional benefits specified in the Participant&#8217;s Participation Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">CIC Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Upon a Participant&#8217;s CIC Qualifying Termination, subject to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, such Participant will receive&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">A lump sum payment in an amount equal to the Participant&#8217;s CIC Severance Multiplier multiplied by the sum of the Participant&#8217;s Base Salary plus the Participant&#8217;s Target Bonus, payable within 30 days following the date the Release becomes effective and irrevocable&#59; provided, that if the period during which the Release could become effective and irrevocable spans two calendar years, payment shall occur in the second calendar year&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">Any annual bonus earned but unpaid for the year immediately preceding the year in which the Termination Date occurs based on actual performance for such year, payable at the time such bonuses are paid to other Company employees and in all events in the year during which the Termination Date occurs&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">A lump sum payment in an amount equal to (x) the Participant&#8217;s CIC COBRA Multiplier multiplied by (y) the monthly premiums for the Participant&#8217;s and the Participant&#8217;s covered dependents&#8217; participation in the Company&#8217;s group health plans pursuant to COBRA, each determined as of the Termination Date, payable within 30 days following the date the Release becomes effective and irrevocable&#59; provided, that if the period during which the Release could become effective and irrevocable spans two calendar years, payment shall occur in the second calendar year&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of the Participant&#8217;s then outstanding equity-based awards shall immediately accelerate and become vested or nonforfeitable as of the later of (x) the Termination Date or (y) the effective date of the Release&#59; provided, however, that any performance-based vesting conditions shall be deemed to have been met based on the greater of target or, if determinable, actual performance, subject to any alternative treatment provided under the terms of the applicable award agreement or other applicable agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, in no event shall any Participant receive Severance Benefits for both a Qualifying Termination and a CIC Qualifying Termination. </font><font style="color:#002060;font-family:'Times New Roman',serif;font-size:11.5pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Other Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. In the event that a Participant&#8217;s employment is terminated other than as the result of a Qualifying Termination or CIC Qualifying Termination, then such Participant shall not be entitled to receive any payments or benefits under this Plan.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Payment of the Severance Benefits shall be subject to (i) the Participant&#8217;s execution (and non-revocation) of a general release of claims in a form provided by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Release</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) within the time period specified therein and (ii) the Participant&#8217;s continued compliance with all restrictive covenant obligations between the Participant and the Company (and its Affiliates).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Repayment of Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">If following the Participant&#8217;s Termination Date, the Company wishes to rehire, in any capacity, any Participant who is receiving Severance Benefits and such Participant accepts the Company&#8217;s offer of employment, such Participant will no </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#002060;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">longer be eligible to receive any portion of the Severance Benefits that remain unpaid.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">If, following the Participant&#8217;s receipt of all or any portion of the Severance Benefits, it is determined that no Qualifying Termination (or CIC Qualifying Termination) occurred, the Participant must repay to the Company all Severance Benefits received. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(f.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.93pt">Administration</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">In the event of any conflict or inconsistency between another document and the terms of the Plan, the terms and conditions of the Plan shall govern and control&#59; provided, however, that a Participant&#8217;s Participation Agreement will govern their participation in the Plan to the extent of any conflict between such Participation Agreement and the Plan.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Plan shall be administered by the Committee in its sole and absolute discretion, and all determinations by the Committee shall be final, binding and conclusive on all parties and be given the maximum possible deference allowed by law. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Committee shall have the authority, consistent with the terms of the Plan, to (i) designate Participants, (ii) determine the terms and conditions relating to the Severance Benefit, if any, (iii) interpret, administer, reconcile any inconsistency, correct any defect or supply any omission in the Plan, (iv) establish, amend, suspend or waive any rules and procedures with respect to the Plan, and (v) make any other determination and take any other action that the Committee deems necessary or desirable for administration of the Plan, including the timing and amount of payments. The Committee may delegate to one or more officers of the Company the authority to act on behalf of the Committee.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(g.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.09pt">Funding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. The obligations of the Company under the Plan are not funded through contributions to a trust or otherwise, and all benefits shall be payable from the general assets of the Company. Nothing contained in the Plan shall give a Participant any right, title or interest in any property of the Company. Participants shall be mere unsecured creditors of the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(h.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.09pt">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Compliance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding anything herein to the contrary, this Plan is intended to be interpreted and applied so that the payments and benefits set forth herein either shall be exempt from the requirements of Section 409A of the Code or shall comply with the requirements of Section 409A of the Code, and accordingly, to the maximum extent permitted, this Plan shall be interpreted to be exempt from or in compliance with Section 409A of the Code. For any payments or benefits subject to Section 409A of the Code and to the extent required to comply with Section 409A of the Code, a transaction or series of related transactions will not be considered to be a Change in Control unless such transaction or series of transactions would also be a change in the ownership or effective control, or in the ownership of a substantial portion of the assets, of the Company under Section 409A of the Code. To the extent that the Company determines that any provision of this Plan would cause a Participant to incur any additional tax or interest under Section 409A of the Code, the Company shall be entitled to reform such provision to attempt to comply with or be exempt from Section 409A of the Code. To the extent that any provision hereof is modified in order to comply with Section 409A of the Code, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to Participants and the Company without violating the provisions of Section 409A of the Code. Notwithstanding any of the foregoing to the contrary, none of the Company or its Affiliates or any of their officers, directors, members, employees, agents, advisors, predecessors, successors, or equity holders shall have any liability for the failure of this Plan to be exempt from, or to comply with, the requirements of Section 409A of the Code. Each payment or benefit </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#002060;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">provided hereunder shall be a payment in a series of separate payments for purposes of Section 409A of the Code.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding anything in this Plan to the contrary, a termination of employment shall not be deemed to have occurred for purposes of any provision of this Plan unless such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Specified Employee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding anything in this Plan to the contrary, if a Participant is deemed to be a &#8220;specified employee&#8221; within the meaning of Section 409A of the Code, any payments or benefits due upon a termination of Participant&#8217;s employment under any arrangement that constitutes a &#8220;deferral of compensation&#8221; within the meaning of Section 409A of the Code (whether under this Plan or any other plan, program or payroll practice) and which do not otherwise qualify under the exemptions under Treasury Regulations Section 1.409A-1 (including the short-term deferral exemption and the permitted payments under Treasury Regulations Section 1.409A-1(b)(9)(iii)(A)), shall be delayed and paid or provided to Participant in a lump sum on the earlier of (i) the date which is six months and one day after Participant&#8217;s &#8220;separation from service&#8221; (as such term is defined in Section 409A of the Code) for any reason other than death, and (ii) the date of Participant&#8217;s death.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.54pt">Amendment or Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. The Committee may amend or terminate the Plan at any time, without notice, and for any or no reason, except as prohibited by law&#59; provided, however, that any termination of the Plan or any amendment of the Plan that is materially adverse to a Participant&#8217;s rights under the Plan will not be effective with respect to such Participant until the date that 12 months following the date of such termination or amendment. Any action of the Company in amending or terminating the Plan will be taken in a non-fiduciary capacity. During a 12-month period beginning on a Change in Control, the Company and the Committee may not, without a Participant&#8217;s written consent, amend or terminate the Plan in any way, nor take any other action, that (i) prevents the Participant from becoming eligible for Severance Benefits under the Plan, or (ii) reduces or alters to the detriment of the Participant the Severance Benefits payable, or potentially payable, to a Participant under the Plan (including imposing additional conditions). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(j.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.54pt">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Nothing in this Plan or any other act of the Company shall be considered effective to change a Participant&#8217;s status as an at-will employee or guarantee any duration of employment. Either the Company or a Participant may terminate the employment relationship at any time, for any reason or no reason, and with or without advance notice.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(k.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.09pt">Transfer and Assignment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. In no event may any Participant sell, transfer, anticipate, assign, encumber or otherwise dispose of any right or interest under the Plan. At no time will any such right or interest be subject to the claims of creditors or liable to attachment, execution, or other legal process.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(l.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.54pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. If any provision of the Plan is held invalid or unenforceable, its invalidity or unenforceability will not affect any other provision of the Plan, and the Plan will be construed and enforced as if such provision had not been included.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(m.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.04pt">Successors</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Any successor to the Company of all or substantially all of the Company&#8217;s business or assets (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or other transaction) will assume the obligations under the Plan and agree expressly to perform the obligations under the Plan in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under the Plan, the term &#8220;Company&#8221; will include any successor to the Company&#8217;s business or assets which become bound by the terms of the Plan by operation of law, or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(n.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.09pt">Withholding&#59; Taxes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. The Company shall withhold from any Severance Benefits all federal, state and local income or other taxes required to be withheld therefrom and any other required payroll deductions.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#002060;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(o.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.09pt">Compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Benefits payable hereunder shall not constitute compensation under any other plan or arrangement, except as expressly provided in such plan or arrangement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(p.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.09pt">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Titles and headings to Sections hereof are for the purpose of reference only and shall in no way limit, define or otherwise affect the provisions hereof. Unless the context requires otherwise, all references to laws, regulations, contracts, agreements, plans and instruments refer to such laws, regulations, contracts, agreements, plans and instruments as they may be amended from time to time, and references to particular provisions of laws or regulations include a reference to the corresponding provisions of any succeeding law or regulation. All references to &#8220;dollars&#8221; or &#8220;$&#8221; in the Plan refer to United States dollars. The word &#8220;or&#8221; is not exclusive. The words &#8220;herein&#8221;, &#8220;hereof&#8221;, &#8220;hereunder&#8221; and other compounds of the word &#8220;here&#8221; shall refer to the entire Plan, including all Exhibits attached hereto, and not to any particular provision hereof. Wherever the context so requires, the masculine gender includes the feminine or neuter, and the singular number includes the plural and conversely. All references to &#8220;including&#8221; shall be construed as meaning &#8220;including without limitation.&#8221; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(q.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.09pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. This Plan and the Participation Agreements represent the entire agreement of the Company and the Participants with respect to the subject matter hereof and supersede all prior understandings, whether written or oral. For the avoidance of doubt, no Participant will be eligible for any other severance benefits under any employment agreement or letter agreement, except as provided under the terms of the Crescent Biopharma, Inc. 2025 Stock Incentive Plan or any successor equity incentive plan adopted by the Company and any award agreements or other agreements governing the terms of awards thereunder. For the avoidance of doubt, this Plan and the Participation Agreement shall not modify any employment agreement or letter agreement with respect to any terms that are not covered by the subject matter hereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(r.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.93pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. The provisions of the Plan will be construed, administered, and enforced in accordance with ERISA and, to the extent applicable, the laws of the State of Massachusetts without regard to its choice of law provisions that would require the application of the laws of a different jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(s.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">Claims and Appeals</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Claims Procedure</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Any employee or other person who believes he or she is entitled to any payment under the Plan may submit a claim in writing to the Committee within 90 days of the earlier of (i) the date the claimant learned the amount of his or her benefits under the Plan or (ii) the date the claimant learned that he or she will not be entitled to any benefits under the Plan. If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The notice also will describe any additional information needed to support the claim and the Plan&#8217;s procedures for appealing the denial. The denial notice will be provided within 90 days after the claim is received. If special circumstances require an extension of time (up to 90 days), written notice of the extension will be given within the initial 90-day period. This notice of extension will indicate the special circumstances requiring the extension of time and the date by which the Committee expects to render its decision on the claim.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Appeal Procedure</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. If the claimant&#8217;s claim is denied, the claimant (or his or her authorized representative) may apply in writing to the Committee for a review of the decision denying the claim. Review must be requested within 60 days following the date the claimant received the written notice of their claim denial or else the claimant loses the right to review. The claimant (or representative) then has the right to review and obtain copies of all documents and other information relevant to the claim, upon request and at no charge, and to submit issues and comments in writing. The Committee will provide written notice of its decision on review within 60 days after it receives a review request. If additional time (up to 60 days) is needed to review the request, the claimant (or representative) will be given written notice of the reason for the delay. This notice of extension will indicate the special circumstances requiring the extension of time and the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#002060;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">date by which the Committee expects to render its decision. If the claim is denied (in full or in part), the claimant will be provided a written notice explaining the specific reasons for the denial and referring to the provisions of the Plan on which the denial is based. The notice also will include a statement that the claimant will be provided, upon request and free of charge, reasonable access to, and copies of, all documents and other information relevant to the claim and a statement regarding the claimant&#8217;s right to bring an action under Section 502(a) of ERISA.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(t.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26.54pt">Certain Excise Taxes</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. If it is determined by a nationally recognized United States public accounting firm selected by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Auditors</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that any payment or benefit in the nature of compensation made or provided to a Participant in connection with such Participant&#8217;s employment with the Company (collectively, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), would be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Parachute Tax</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Tier 1, Tier 2 and Tier 3 Participants</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. The Company shall pay to any such Participant in Tier 1, Tier 2 or Tier 3, prior to the time the Parachute Tax is payable with respect to such Payment, an additional payment (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Gross-Up Payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in an amount such that, after payment by such Participant of all taxes (including any Parachute Tax) imposed upon the Gross-Up Payment, such Participant retains an amount of the Gross-Up Payment equal to the Parachute Tax imposed upon the Payment.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">The amount of any Gross-Up Payment shall be determined by the Auditors, subject to adjustment, as necessary, as a result of any Internal Revenue Service position. For purposes of making the calculations required by this Agreement, the Auditors may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">The federal tax returns filed by such Participant (and any filing made by a consolidated tax group which includes the Company) shall be prepared and filed on a basis consistent with the determination of the Auditors with respect to the Parachute Tax payable by such Participant. Such Participant shall make proper payment of the amount of any Parachute Tax, and at the request of the Company, provide to the Company true and correct copies (with any amendments) of such Participant&#8217;s federal income tax return as filed with the Internal Revenue Service, and such other documents reasonably requested by the Company, evidencing such payment. If, after the Company&#8217;s payment to such Participant of the Gross-Up Payment, the Auditors determine in good faith that the amount of the Gross-Up Payment should be reduced or increased, or such determination is made by the Internal Revenue Service, then within 10 business days of such determination, such Participant shall pay to the Company the amount of any such reduction, or the Company shall pay to such Participant the amount of any such increase.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">Prior to determination of any Gross-Up Payment, the Company shall undertake all reasonable efforts to reduce or eliminate the Parachute Tax, and such Participant shall fully cooperate in all such efforts to remain eligible to receive any Gross-Up Payment.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Tier 4 and Tier 5 Participants</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. A Participant in Tier 4 or Tier 5 will be entitled to receive </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">either </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(x) the  full amount of the Payments, or (y) a portion of the Payments having a value equal to $1 less than three times such Participant&#8217;s &#8220;base amount&#8221; (as such term is defined in Section 280G(b)(3)(A) of the Code), whichever of clauses (x) and (y), after taking into account applicable federal, state, and local income and employment taxes and the Parachute Tax, results in the receipt by such Participant on an after-tax basis, of the greatest portion of the Payments.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#002060;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Any determination required under this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 20(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> shall be made in writing by the Auditor, whose determination, absent manifest error, shall be conclusive and binding for all purposes upon the Company and such Participant. For purposes of making the calculations required by this Agreement, the Auditors may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">If there is a reduction of the Payments pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 20(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, such reduction shall occur in accordance with Section 409A of the Code and in the following order&#58; (1) any cash severance payable by reference to such Participant&#8217;s base salary or annual bonus, (2) any other cash amount payable to such Participant, (3) any employee benefit valued as a &#8220;parachute payment,&#8221; and (4) acceleration of vesting of any outstanding equity award. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">For the avoidance of doubt, in the event that additional Payments are made to such Participant after the application of the cutback in this </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 20(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, which additional Payments result in the cutback no longer being applicable, the Company shall pay such Participant an additional amount equal to the value of the Payments that were originally cut back. The Company shall determine at the end of each calendar year whether any such restoration is necessary based on additional Payments (if any) made during such calendar year and shall pay such restoration by March 15 of the calendar year following such calendar year. In no event whatsoever shall a Participant in Tier 4 or Tier 5 be entitled to a tax gross-up or other payment in respect of any excise tax, interest or penalties that may be imposed on the Payments by reason of the application of Section 280G or Section 4999 of the Code. Nothing in this Plan shall require the Company to be responsible for, or have any liability or obligation with respect to, such Participant&#8217;s excise tax liabilities under Section 4999 of the Code.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#002060;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="i6b69201f56914b5b8cf6be04810c8cf4_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:14.247%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.419%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Tier</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Severance Multiplier</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">COBRA Multiplier </font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CIC Severance Multiplier</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CIC COBRA Multiplier </font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Tier 1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">1.0x</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">1.5x</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">18</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Tier 2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">1.0x</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">1.25x</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">15</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Tier 3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">0.75x</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">1.0x</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Tier 4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">0.75x</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">1.0x</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Tier 5</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">0.5x</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">0.75x</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font><br></font></div></div></div><div id="i6b69201f56914b5b8cf6be04810c8cf4_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">CRESCENT BIOPHARMA, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EXECUTIVE SEVERANCE PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">FORM OF PARTICIPATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This Participation Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made and entered into by and between ______________ (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Cresent Biopharma, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) effective as of ______________, 20____.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Company maintains the Cresent Biopharma, Inc. Executive Severance Plan (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Capitalized terms used but not defined in this Agreement have the meanings ascribed to them in the Plan. The Plan provides Severance Benefits in connection with the Participant&#8217;s Qualifying Termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">By signing this Agreement, the Participant acknowledges and agrees that the Participant has read and understands all of the terms of the Plan and this Agreement and that the Participant agrees to participate in the Plan as a Tier &#91;__&#93; Participant. The Participant acknowledges and agrees that such participation is subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#91;In addition to the Severance Benefits provided under the Plan, upon a Qualifying Termination, 30% of the unvested portion of the Participant&#8217;s then outstanding equity awards subject to only time-based vesting shall immediately accelerate and become vested as of the later of (i) the Termination Date, or (ii) the effective date of the Release&#59; provided that no such acceleration of vesting shall occur if the Termination Date precedes March 17, 2026.&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Miscellaneous&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.71pt">This Agreement will be construed, administered, and enforced in accordance with ERISA and, to the extent applicable, the laws of the State of Massachusetts without regard to its choice of law provisions that would require the application of the laws of a different jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.09pt">This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.71pt">This Agreement and the Plan represent the entire agreement between the parties with respect to the subject matter hereof. For the avoidance of doubt, the Participant will no longer be eligible for any other severance benefits under any employment agreement or letter agreement, except as provided under the terms of the Crescent Biopharma, Inc. 2025 Stock Incentive Plan or any successor equity incentive plan adopted by the Company and any award agreements or other agreements governing the terms of awards thereunder. If any dispute should arise under this Agreement, it shall be settled in accordance with the terms of the Plan. For the avoidance of doubt, the Plan and this Agreement shall not modify any employment agreement or letter agreement with respect to any terms that are not covered by the subject matter hereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.09pt">This Agreement shall be binding on the executors, heirs, administrators, successors and assigns of the Participant and the successors and assigns of Company and shall inure to the benefit of the respective executors, heirs, administrators, successors and assigns of the Company.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Signature page follows.&#93; </font></div><div style="border-bottom:0.52pt solid #002060;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#58; For CEO and COO only.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Participant and the Company hereto have executed this Agreement as of the date first set forth above.</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">CRESCENT BIOPHARMA, INC.</font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;</font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">PARTICIPANT</font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>pressrelease-q22025.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4ad4e64e0c104a00930d54733483c695_1"></div><div style="min-height:87.66pt;width:100%"><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:168px"></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Crescent Biopharma Reports Second Quarter 2025 Financial Results <br>and Recent Business Highlights</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Recent Leadership Appointments Bring Deep Experience in Oncology Drug Development, Clinical Operations and Building Biotechnology Companies</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">On Track to Submit IND Application for CR-001, a PD-1 x VEGF Bispecific Antibody, in Fourth Quarter of 2025, with Proof-of-Concept Clinical Data Expected in Second Half of 2026 </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Waltham, Mass., July 31, 2025 --</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> Crescent Biopharma, Inc. (&#8220;Crescent&#8221; or the &#8220;Company&#8221;) (Nasdaq&#58; CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the second quarter ended June 30, 2025, and recent business highlights. </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8220;The second quarter of 2025 was momentous for Crescent. We bolstered our leadership team, completed our merger and began trading on Nasdaq while also closing a substantial financing with a premier group of healthcare investors that will support the advancement of our portfolio of next generation therapeutics for solid tumors to important inflection points,&#8221; said Joshua Brumm, chief executive officer of Crescent. &#8220;Our lead program, CR-001, a PD-1 x VEGF bispecific antibody, is designed to transform the immuno-oncology standard of care, and we are on track to submit an IND by the end of 2025. This would enable dosing the first patients in our global Phase 1 trial in early 2026, with proof-of-concept data expected later that year. In addition, we expect the first of our two ADCs to enter the clinic in mid-2026. We have a tremendous opportunity ahead of us, and we remain focused on rapidly advancing our programs as we work toward delivering the next wave of treatments to those living with cancer.&#8221;</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Recent Business Highlights &#38; Upcoming Milestones</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:120%">Corporate</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:13pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.45pt">Crescent appointed new leadership bringing experience in oncology drug development, clinical operations and building biotech companies, including Joshua Brumm as chief executive officer and member of the board of directors&#59; Jonathan McNeill, M.D., as president and chief operating officer&#59; Ellie Im, M.D., as chief medical officer&#59; Rick Scalzo, MBA, as chief financial officer&#59; Jan Pinkas, Ph.D., as chief scientific officer&#59; Amy Reilly as chief communications officer&#59; and Tanya Sengupta, MBA, as executive vice president, chief of strategy and operations. </font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:13pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.45pt">The Company appointed David Lubner to Crescent&#8217;s board of directors.</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:13pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.45pt">Crescent completed its merger with GlycoMimetics, Inc. and began trading on the Nasdaq Capital Market on June 16, 2025, under the ticker symbol &#8220;CBIO.&#8221; The Company also closed a previously announced private financing of $200 million in gross proceeds.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.66pt;width:100%"><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:168px"></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:133%">Pipeline</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">CR-001, a PD-1 x VEGF bispecific antibody</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:13pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.45pt">Crescent&#8217;s lead program, CR-001, is a tetravalent PD-1 x VEGF bispecific antibody intentionally designed to replicate the cooperative pharmacology of ivonescimab, which demonstrated superior efficacy compared to the current market leader, pembrolizumab, in a large third-party Phase 3 trial in non-small cell lung cancer.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.82pt;font-weight:400;line-height:120%;position:relative;top:-3.67pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> Crescent remains on track to submit an Investigational New Drug (IND) application in the fourth quarter of 2025 and expects to report proof-of-concept clinical data from a global Phase 1 trial in patients with solid tumors in the second half of 2026.<br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">CR-002 and CR-003, novel antibody-drug conjugates (ADCs)</font></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:13pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.45pt">CR-002 and CR-003 are novel ADCs with topoisomerase inhibitor payloads that are being developed as single agents and in combination with CR-001. Crescent expects to submit an IND application for CR-002 in mid-2026.<br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Second Quarter 2025 Financial Results</font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Cash position&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;Cash was $152.6 million as of June 30, 2025, which is anticipated to fund operations through 2027. </font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Research and development (R&#38;D) expenses&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;R&#38;D expenses were $12.1 million for the three months ended June 30, 2025. </font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">General and administrative (G&#38;A) expenses&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;G&#38;A expenses were $8.9 million for the three months ended June 30, 2025. </font></div><div style="margin-bottom:8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Net loss&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;Net loss was $21.8 million, or $4.93 per basic and diluted share, for the three months ended June 30, 2025.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10.5pt;font-weight:400;line-height:120%"><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">About Crescent Biopharma</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Crescent Biopharma&#8217;s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company&#8217;s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit&#160;www.crescentbiopharma.com&#160;and follow the Company on&#160;LinkedIn&#160;and&#160;X.<br><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Certain statements in this press release, other than purely historical information, may constitute &#34;forward-looking statements&#34; within the meaning of the federal securities laws, including for purposes of the &#34;safe harbor&#34; provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Crescent&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.66pt;width:100%"><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:168px"></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">and business including, without limitation, Crescent&#8217;s ability to achieve the expected benefits or opportunities with respect to CR-001, CR-002 and CR-003, including the expected timelines of regulatory filings for CR-001 and CR-002 and initial clinical data for CR-001, the potential for CR-001 to replicate the cooperative pharmacology of ivonescimab in clinical trials, the potential for CR-002 and CR-003 to act as single agents and in combination with CR-001, the anticipated benefits of the management and board of directors changes, and Crescent&#8217;s anticipated cash runway. The words &#34;opportunity,&#34; &#34;potential,&#34; &#34;milestones,&#34; &#34;pipeline,&#34; &#34;can,&#34; &#34;goal,&#34; &#34;strategy,&#34; &#34;target,&#34; &#34;anticipate,&#34; &#34;achieve,&#34; &#34;believe,&#34; &#34;contemplate,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intends,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;possible,&#34; &#34;project,&#34; &#34;should,&#34; &#34;will,&#34; &#34;would&#34; and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Crescent will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Crescent&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to those uncertainties and factors more fully described in Crescent&#8217;s most recent filings with the&#160;Securities and Exchange Commission (including its Quarterly Report on Form 10-Q and registration statement on Form S-4, most recently amended on May 12, 2025 and declared effective by the SEC on May 14, 2025), as well as risk factors associated with companies, such as Crescent, that operate in the biopharma industry. Should one or more of these risks or uncertainties materialize, or should any of Crescent&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Crescent does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Crescent.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.66pt;width:100%"><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:168px"></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:133%">Crescent Biopharma, Inc.<br>Condensed Consolidated Statement of Operations<br>(in thousands, except share and per share data)<br>(Unaudited)</font></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:57.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Three Months Ended<br>June 30, 2025</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Six Months Ended<br>June 30, 2025</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Operating expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">12,081&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">22,708&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">8,949&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">12,547&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">21,030&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">35,255&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(21,030)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(35,255)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Other expense</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(760)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(1,683)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Net loss and comprehensive loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(21,790)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(36,938)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Net loss per share attributable to ordinary shareholders, basic and diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(4.93)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(14.11)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Net loss per share attributable to Series A non-voting convertible preferred shareholders, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(4,930.97)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(14,104.9)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Weighted-average ordinary shares outstanding used in computing net loss per share to ordinary shareholders, basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">3,856,925&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">2,331,339&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Weighted-average ordinary shares outstanding used in computing net loss per share to Series A non-voting convertible preferred shareholders, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">565&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">286&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%"><br>Summary Balance Sheet Data<br>(in thousands)<br>(Unaudited)</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">June 30, 2025</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Cash</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">152,645&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">34,766&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">4,788&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">851&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Total Assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">157,433&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">35,617&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:134%">Liabilities and Shareholders' Equity (Deficit)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">18,179&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">47,096&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Shareholders' equity (deficit) and convertible preferred shares</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">139,254&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">(11,479)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">Total liabilities and shareholders' equity (deficit)</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">157,433&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:134%">35,617&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.66pt;width:100%"><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:168px"></div></div><div style="margin-bottom:8pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:115%">Reference&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">1. Xiong, Anwen et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2)&#58; a randomised, double-blind, phase 3 study in China. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:115%">The Lancet</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">, 2025&#59; 405(10481)&#58; 839-849.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:115%">Contact</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:133%">Amy Reilly</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:133%">Chief Communications Officer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:133%">amy.reilly&#64;crescentbiopharma.com </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:133%">617-465-0586</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cbio-20250729.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:77c2f864-6fb7-459c-9e5f-aaeb1b69cd1d,g:111b592c-dd60-41d3-86a7-d658a669c678-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cbio="http://crescentbiopharma.com/20250729" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://crescentbiopharma.com/20250729">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20250729_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20250729_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://crescentbiopharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cbio-20250729_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:77c2f864-6fb7-459c-9e5f-aaeb1b69cd1d,g:111b592c-dd60-41d3-86a7-d658a669c678-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_7a0d9354-8e50-4b2b-a3a9-950b7c83fef9_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a85e961f-d73f-4ce1-96ea-19c203282f28_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9dd9ae65-1a08-4454-ade7-c2e3d3ba3953_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c4e57619-a8df-43fc-8f5e-861c0f1e8a2a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_54dd3fc0-c46c-4793-a6c6-5e70fffd0612_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_53a64d5d-1422-4afe-8877-ded1441571ce_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5f03ab46-8571-49eb-a4ee-a5140d559fa1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2db9901a-a2c3-4769-b399-df483eda16cc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_1564be0e-bc8b-4d69-8b96-983bd3fc014b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_af96815e-3fad-4141-8df8-359920190230_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b2fd802e-263a-456e-9ee1-19dda3e59c2d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0a246a11-945a-4025-9f9a-deb56d0a63c4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b85cee90-a1a4-4a02-bf26-2f20a1dec0fd_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1d543b09-9136-438d-a581-e1ae570c57de_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_48727579-78ca-41cf-988b-9d4a5acf8239_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f34ccf57-b9b2-4cb6-809a-bd624631cc24_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2ac40e52-0cbf-4bf4-a3bb-6154a0a4fb66_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9524d0bf-491f-4730-a390-98be5d1cd6a3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1bded25d-45fb-4066-a618-71cf23798573_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_33e61077-bb05-4bef-923d-a1846c4f3c5e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_55f829ab-b15e-413e-a40b-47e562fc6faa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4df42551-21ef-4721-bc72-f5d00389470f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_984352bd-f0df-47ea-b88a-09e73303abd2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>cbio-20250729_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:77c2f864-6fb7-459c-9e5f-aaeb1b69cd1d,g:111b592c-dd60-41d3-86a7-d658a669c678-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://crescentbiopharma.com/role/Cover" xlink:type="simple" xlink:href="cbio-20250729.xsd#Cover"/>
  <link:presentationLink xlink:role="http://crescentbiopharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a78dee6a-0cb2-4bcd-8062-3e01631653a3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_DocumentType_a78dee6a-0cb2-4bcd-8062-3e01631653a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f8b92198-1242-43d7-aa16-acbe4cdb0bae" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_DocumentPeriodEndDate_f8b92198-1242-43d7-aa16-acbe4cdb0bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a6c5bc7e-a6ee-459c-a27b-65be5d745f0a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityRegistrantName_a6c5bc7e-a6ee-459c-a27b-65be5d745f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_22924b49-2649-4e9d-a825-2d62d89b5fd8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityIncorporationStateCountryCode_22924b49-2649-4e9d-a825-2d62d89b5fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5836882b-0be5-4fec-95d3-1126e4e5ed67" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityFileNumber_5836882b-0be5-4fec-95d3-1126e4e5ed67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ad50c8a0-16ba-48ae-a98c-5689559b9f2a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityTaxIdentificationNumber_ad50c8a0-16ba-48ae-a98c-5689559b9f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9165a536-cd94-4900-895a-7068580ef618" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityAddressAddressLine1_9165a536-cd94-4900-895a-7068580ef618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_efdac4aa-2800-4f41-bc55-4ef77b21b91d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityAddressCityOrTown_efdac4aa-2800-4f41-bc55-4ef77b21b91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fd142b1c-a8ff-4d7f-8e38-bab0acd5f6ac" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityAddressStateOrProvince_fd142b1c-a8ff-4d7f-8e38-bab0acd5f6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2b76b77e-ae66-4723-94e9-cb81e29b575e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityAddressPostalZipCode_2b76b77e-ae66-4723-94e9-cb81e29b575e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d38bbe42-db94-47dc-9ae7-629ddd194c51" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_CityAreaCode_d38bbe42-db94-47dc-9ae7-629ddd194c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f4e47c66-cad4-4911-94b5-38b158f787d2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_LocalPhoneNumber_f4e47c66-cad4-4911-94b5-38b158f787d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7eb11177-f28a-4ab8-80f7-bfd57ecb654b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_WrittenCommunications_7eb11177-f28a-4ab8-80f7-bfd57ecb654b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a744bb2a-1913-46cd-86bd-a545aa98bed0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_SolicitingMaterial_a744bb2a-1913-46cd-86bd-a545aa98bed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_94b98ba9-8dd3-46fe-9e1a-94a4f0789704" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_PreCommencementTenderOffer_94b98ba9-8dd3-46fe-9e1a-94a4f0789704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_95af1828-8294-419e-bba8-0305c61ee66b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_95af1828-8294-419e-bba8-0305c61ee66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cdc129bc-5e11-4ebe-8819-dc78f98aa9a4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_Security12bTitle_cdc129bc-5e11-4ebe-8819-dc78f98aa9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5cb4013d-f942-40c5-b4a5-b2860c495381" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_TradingSymbol_5cb4013d-f942-40c5-b4a5-b2860c495381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8c36026f-55af-49d3-9c47-24614e7f545f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_SecurityExchangeName_8c36026f-55af-49d3-9c47-24614e7f545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b6936b3a-b8d4-4baa-b362-9a421d5a4b7e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityEmergingGrowthCompany_b6936b3a-b8d4-4baa-b362-9a421d5a4b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_33ad07f8-064c-4f66-b0d6-230c6a8d4df6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_EntityCentralIndexKey_33ad07f8-064c-4f66-b0d6-230c6a8d4df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_809986df-41d9-4f4a-8faf-1d8c5723ecf2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_23e6cb7a-cafa-4733-8b1d-c2bdc64f6e21" xlink:to="loc_dei_AmendmentFlag_809986df-41d9-4f4a-8faf-1d8c5723ecf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $U UT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M JS A@0>N/$GEF80P2QDJ4E2;MS6TOV_3UT/<AFN6U,>\%&K%U4N;EOK;O\
MKZ:['J5%%%<)Z 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\6>.O@M\-K?1-4\;:@+SQ'=17,LGVB3<[X42.PB3=([;$"KECQTQ\??M9?\
M! 3P)^TI^U'J?Q^T?X\WGAW3/$FHB^\2:$-$6XD:<X\UK>8RJ(_,()PR-M9B
M?F&%'NY-Q=AY\05,5CL544/9\L6XQO?1M-1BUOS.+MVN^A\WGO!N*CPY2PF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "BBB@ HZT44 5;'0]%TR*:#3=(M;>.X<O.D%NJ"1CU+ #DGU-?G]8_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KS3]JS]KKX#_L6?#%/BY^T+XO;1]&
MFU*+3[5X;*2XEN+F17=8TCC4LQV1R,>P"$YKTNO*?BM\+/V1/V^_AO>_#+XB
M6_AOXB>'M,UM3>6NGZUYGV'4(0PP9;64/!,JNRD!E;:[ \$@].$CA_K$98A2
M=--<W+:]O*^E_4Y\2ZWL6J+2FU[O-M?SMK;T-#2/ O[,/[2LG@W]J6U^'_AC
MQ3=QZ;#?^"_%]WHL4MU;V\H\V-X9)$\R/[VX#@JQ)P#FO+_VR_\ @F[X?_;$
M_:"^%GQ[U7XT>(?#LWPRU(746E:6H:.^ GCF&UBP-NY:,*T@#$I@8& :L_MX
M?L2>+_VA/V,X?V6?V8OB1'\-?[-FL%TO[(98K8V5LI063F$[UBQM/&>8ER""
M:]5_9J^&/BWX+? 'PA\)_'GQ!N?%6L^'M M['4O$-WN\R^EC0 R'<2Q] 6)8
M@#))S7H4\3+!4HXK#8AJ:<HJ+5W&#6]W[NMVK+KJO+BG06+J2P^(H^Y:,G).
MR<D]K+72R>O30/C/XJ^.GAF_\(Q?!;X5Z=XF@U'Q7;6GBZ:_UM;,Z3I3!O.O
M(P0?/=,#$8Y.>G<=Q117E2FI0C%12MUUN_76VGDD>E&#C-RNW?II9>FG7SN%
M%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &)\0/AK
M\/?BOX=?PC\3?!&E>(-+D<.]AK%A'<1;AT;:X(##/!'([5\>?\%0?CE\:/V$
M?AEX*\-?L;^"--\*Z!>WERNHW^D>'('AM9%\LQP",QF-#)ND8L5W-LX/!K[>
MI'C21=LB!AZ$9KU,JS*.7XN$ZU/VM.+;=.3]UNS5[:JZWV9X'$&23S?+ZM+"
MUGAZ\TDJT5[\4FG9.Z=G:VDEN?FS^VA^RA^V#^WW\!/A'^T+I?A.)_$\/AAX
M?$7A26=;-D:23<EU$LS*J^8H#,A(*@H!G!QTGP-_X)J?![2/V5M)_9X_;9^(
M.FZ/XMU+Q/<:UH%I9>)+>*\T\S10P&WA,A99M_D N%5EW$8.5S7UI\4/CYXS
M^'_QY\#_  ?T7X%Z]KNF>+/._M'Q78 _9='V=/-PA'N=S)P1MW'BOSW_ ."C
MG[ W[9/Q2_;+UKQUX)\ ZCXFTCQ#+;MHVI6MPGE6<:Q(GDR;F'D!&5N3A2#N
MSDD#[W)<SQV8TZ> JUX82BN:K3DK<WQ.T;N222N]&DVEU3/Q[BK(<IR2M6S?
M#X2IF.);A0K0DI<OP1;J64&VY)1U3<5*6EFK'M.M?M5?L2?\$MKMOV//"WPX
MU_Q$HE2[\77A,$S>;,B$&7S"JROY>P[%545<#.<UN_MH_P#!1/Q_^SK<?#5/
MV:_A/IFM>%_&.D1:A9WLMA-Y=VDC#9:6ZQ%?+EVE6((8CS%^7@YI_&3_ (([
M^"OC//X>^)7Q!^-5_I&N6?A?3K7QU=Q6Z3Q:C/:VD<,MTLDC+Y3,(^68,#@,
M5SG/K?[/'[9/[$>I:?!\!/@E\3(;W_A#M#,=A9/9SJT]M:0_,87D11.P1"3M
M.2 6 (YKBJSR2I&EBZ%*>+J1NZ]^;ENU92;LTM=8V^SOJ>CAZ7%=*IB,LQ>)
MHY;1FXK"<OL^?EC)-PC'F3E[ME.^O.]+IV?O>EW<]_IEO?7-D]M)- DDEM(?
MFB8J"4/N#Q^%3U\6?LB_\%<H_P!IG]HR#X*ZG\(?['LM9-P-!OX=0,TJF.-Y
M0)UV@#<B'E3\IP.0=P^TZ^.S7*,PR;$JCC(<DFE)*Z>C\TWV:/T_AOB;)>*\
M \7EE;VD(R<&[./O))O1I/9I[6U"BBBO,/H HHHH **** "BBB@ HHK%^(GQ
M&\!?"/P3J7Q)^)_B_3]!T#1[5KC4]7U2Z6&"VB'5F9C@>@'4D@#)--)R=D&Q
MM5P?QX_:B_9T_9?\._\ "5?M"_&OPUX/LF4F!M=U:."2XQU6&,G?,W^RBL?:
MOQT_X*1_\'/_ (T\37VH?"C_ ()X:<=%TI2T,WQ'UFR#7ET.A:SMI 5@0]I)
M0SD'(2,C-?DO\1_B?\2/C#XMNO'OQ7\>:OXDUN^??=ZKKFHR75Q*?=Y"3CT'
M0=J^JP'"V)KQ4\0^1=NO^2_'T.*KC(1=HZG]!'QO_P"#H_\ X)W?#BYFTWX6
MZ)XU^($\9(2YTO1ULK-S_P!=+MTDQ[B(U\\>+?\ @[QU5[AX_ G["MO'$"=D
MVK_$!G9O0E([)0OTW'ZU^,-%?14N&LIIK6#EZM_I8Y7BZ[ZV/V#M_P#@[J^+
M:S*UW^Q3X<>//S+'XQN%8_0FW./RKT/X=?\ !W1\*]0N(X?BS^Q=K^DQY DN
M/#WBZ#4#]1'-!;_EN_&OPYHK27#N3R7\*WHY?YB6*KKJ?T]?L[?\' 7_  2_
M_:(N8-(B^/'_  A6ISD!=/\ B!8G30">QN26MA^,M?9&B:YHGB72;?7O#FL6
MNH6-W$)+6]LKA98ID/1D=20P/J#7\7M>X_L>?\%'/VQOV%/$,>K_ +.OQGU+
M3;$S![SPU>O]JTJ\]1):R90$CC>FV0=F%>1B^$J;5\-.S[2V^];?<S>&-?VT
M?UMT5^>O_!+G_@X'_9^_;GO-/^#OQILK7X>?$VXVQ6MC/<YTS6Y3QBTF<Y20
MGI!)\W("-(<X_0JOCL5A,1@JOLZT;/\ K;N=T)QJ*\6%%%%<Q84444 %%%%
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MN4@@@&O2?VZO''B7X9_L5_%KXA>#-2>RU?1?AOK5[IEY&<-;W$=E*T<B^ZL
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M^V1_P4-UC/P-^'OV;PY!/Y6H>-=?9K;2[8C[RB3:6G<=XXE=AD;@H.:^H?\
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M/W(HU. .I.6.69B?7R+)O[2JNI4_AQW\WV_S,,37]DK+=G0?MM_\%!?VH/\
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MOWD8&YBZ[F3U<NXEPN-J*G47))[=4_G_ )F-7"3IJZU1\M_\$V?^"NG[3_\
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M1W<0$HP>=I)0X^92.*_!'_@KE_P0W^+G_!.BYE^+?PZU*[\8_"BYNA''KC0
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M"J\R(W0L ?SK^S3P'#%;>!M%MX$"QQZ3;*BCH (E %=G&$VJ5&/=M_=;_,C
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M/AW<*S>?;W#8]PML/PK]I*_.<YPT<)F=2G':]U\]?U/4H3YZ29_-=_P<N_\
M*5KQ/_V*VB_^DBU\"5]]_P#!R[_RE:\3_P#8K:+_ .DBU\"5^DY3_P BRC_A
M7Y'E5_XTO4_7W_@U?_82T+Q]XZ\3_MV?$+1$NH?"-U_8?@A9X]R+J+Q![JY
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MFFI_,1_P<,^)+CQ'_P %;_BB)I"4L%TBSA7LJII5ID#_ ($6/XU\55]E?\'
MNE7&D?\ !7'XMQW*D&>XTJ=,CJKZ39L/YU\:U^OY;;^SJ-OY(_DCPZO\67JS
M]'_V9?\ @Y7_ &H?V6_V?_"'[._@O]GWX>WFE>#M"@TRRO+\7WGSI&N/,DV3
MA=S'). !D]*[K_B+2_;)_P"C:_AE^6H__)-?*GPT_P""(G_!3[XP?#O0OBO\
M.OV8;C4M \2Z1;ZGHNH)XETQ!<VL\:RQ2;7N0RY1E.& (S@@'BMO_B'^_P""
MN'_1H]U_X5.D_P#R57F5,+PW*HW-PO?7WEO]YJIXNVE_N/I#_B+2_;)_Z-K^
M&7Y:C_\ )-'_ !%I?MD_]&U_#+\M1_\ DFOF_P#XA_O^"N'_ $:/=?\ A4Z3
M_P#)5'_$/]_P5P_Z-'NO_"ITG_Y*J/JG#']S_P "7^8^?&>?W'TA_P 1:7[9
M/_1M?PR_+4?_ ))H_P"(M+]LG_HVOX9?EJ/_ ,DU\W_\0_W_  5P_P"C1[K_
M ,*G2?\ Y*H_XA_O^"N'_1H]U_X5.D__ "51]4X8_N?^!+_,.?&>?W'TA_Q%
MI?MD_P#1M?PR_+4?_DFOS5_: ^,.K_M"?''Q=\=O$&C6>G7_ (Q\1WFLWMCI
M^_R()KF9I72/>2VT,QQDD^]?37_$/]_P5P_Z-'NO_"ITG_Y*H_XA_O\ @KA_
MT:/=?^%3I/\ \E5U85Y%@Y.5&<(M_P!Y?YD3^LU%:2;^1\;5_83^R-=W-_\
MLH_#&^O PFG^'FBR2ACD[C8PDY_$U_-^/^#?W_@K@3C_ (9'NOK_ ,)3I/\
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M^#;G_@FS\?9+C6?!'@W5OAIJ\V6%SX+O]MH7/]ZTG$D2K_LQ"/ZU\$?M _\
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MOHK'BQYE)<NY^BG_ !%I?MD_]&U_#+\M1_\ DFC_ (BTOVR?^C:_AE^6H_\
MR37S?_Q#_?\ !7#_ *-'NO\ PJ=)_P#DJC_B'^_X*X?]&CW7_A4Z3_\ )5>%
M]4X8_N?^!+_,Z.?&>?W'TA_Q%I?MD_\ 1M?PR_+4?_DFC_B+2_;)_P"C:_AE
M^6H__)-?-_\ Q#_?\%</^C1[K_PJ=)_^2J/^(?[_ (*X?]&CW7_A4Z3_ /)5
M'U3AC^Y_X$O\PY\9Y_<?2'_$6E^V3_T;7\,ORU'_ .2:/^(M+]LG_HVOX9?E
MJ/\ \DU\W_\ $/\ ?\%</^C1[K_PJ=)_^2J/^(?[_@KA_P!&CW7_ (5.D_\
MR51]4X8_N?\ @2_S#GQGG]QL_P#!1'_@NO\ M ?\%'_@)!^S_P#%/X->"]$T
MZW\0V^KQ7VA"[\\30QS1JO[V9UVE9FSQGIS7P[7V3_Q#_?\ !7#_ *-'NO\
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M'+O_ "E:\3_]BMHO_I(M? E???\ P<N_\I6O$_\ V*VB_P#I(M? E?K64_\
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M<22>69F8\L:\LT31-9\2ZS:>'/#NE7%]J%_<I;V-E:0F26XF=@J1HJY+,S$
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M;V4HU2RMHMTVJZ)DR2(H'+R0-NE5>ZO,!DE17\\M?VF$ C!%?A__ ,%P/^"
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M\/-)\,_A]>0ZAXHGGB_<ZC<J=]OIP[,78!I!VB5@<%TSYQ_P30_X)3_M$?\
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M/:Z/Y2[?_@C9_P %1[J98(OV(?'09CP9--5!^)9@!^->A_#K_@W?_P""L7Q
MN(TN?V=+;P] Y&;KQ%XHL(50>I2.9Y/R0FOZ<:*TGQ;CVO=A%??_ )B6"I=6
MS\0OV=O^#2GQS>W,&J?M6_M2:;I]N"#/HW@/3GN99!W NKH1K&??R7K],OV,
M_P#@E+^PU^PC%%?_  )^"UG_ &^D>V3Q=KQ^W:J_&"5GD'[D'NL(C4^E?1=%
M>1B\XS'&KEJU';LM%^&_S-H4*5/5(****\PV"BBB@#\P/^#A'_@E_P#M=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0000""*YWXE_ ?X*Z_\  G6/A!JWPI\/2^%W\/SV?]@_V1"+5(!$P"+&%"H
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M#GQHT/X=^+;CQK8ZE:^%KF[M6\-PZBCHK3 2_:'A5OX"#""1P6''(:ON*@
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MX,NC#"XK$0G9J,)KR=O2V_D:U&YPBUU:/G7XM_%O]J__ (+W?M;:!^P9X_\
M@7H_P6TCX2^(4\0_$+1]9\1?:]5(3$+>4OEQF0^7,54(A0>>KL^"N?VQK\T/
M^"QW[-WQI_9Z_:B^&W_!73]C3X?:GKOBKPSJ,&D?$;PSH%C)/-K>F.#&LC1Q
M*S/^[9[=VP2H:!@!Y61^B_P\\;:;\2? >C?$+1K&^M;76]+@OK>UU.S>VN8%
MEC#B.:)P&BD7.&1@"K @]*SS*<*N&HRHI*G9Z+I+[5[MO71KR'23C.2EO^G0
M_'_X/?L_6G[5/_!2K_@H9^SW=0H\GBGP?/:6!D'$=X)8GMI.?[LZ1-_P&O$_
MV-/C1XC_ ."D7Q._8L_8&\26=T\'P3OM1U3Q]!<1MLDCTZ?=9Q2!NRVUM%;_
M %N2*^W?^";GPK^)WA;_ (+<_M:>/O$_PYU[3M"UJ./^Q]:O]'GAM+[_ $B(
M_N9G4)+P"?E)Z5[Y^R-_P2._9]_8Y_:_^(G[8OP\\0:O=ZU\06O=VE7R0BUT
MA+J[%U-';[$#;2ZJ!N)PJ@5ZM;,:&'YXRU?)!P\I.GRO\'^!C&E*=FN[OZ7N
M?,O_  1PX_X+ _MQ_P#8Y#_TXWU?=?[>/QTC_9H_8Q^)_P =1<B*X\-^"K^Y
MTUF. ;TPLELN?]J=XE_&OC+_ ()*_"SXG>#/^"KW[9WC'QA\.->TG2-=\6B3
M1-5U/1YX+;4$_M"];=!*ZA9AAE.4)&&![UU/_!QK_P +F\9?L*Z?^S[\#?AU
MK_B+5/B!XXT^QU"'0M)GNO(LH2UPSRF)6\M/.CMQEL#!/O7#B*<,3G-.#>C4
M+^G*KFD&X8=OU_,\%_X)*:A^PQH'_!%C7?V>?C#^US\*M \2_%JR\07'B#2]
M=\?Z;;W=G-=*]G;F6.28.C"*""7# $;J]A_X-B_CC)\2O^"<[_"G4[Y)+_X;
M^,;_ $GRUE#XM9B+R)@02"N^>= 1Q^[XKV7P#_P1(_X)E^&? NB^&_$'[('@
M_5;_ $_2;:VOM3NK1S+>31Q*CS.=_+.P+$^I-?//_!+OX">,?V%_^"OG[1/[
M-WAGX3:WI7PL\7:;;:[X0U.+2+C^RH7C9)4M8IROE@JE]<1[=V?]' /2MJ^(
MPF.P^)Y&^9M3ULMG9VU[/\"8QG3E"^VQ^G%%%%?-'6%%%% !1110 5YW^TS^
MT[\,OV4?AV/B-\3Y;MK>:\6TLK/3X1)/=3LK-L0,R@8568DD  >I ._\8?BM
MX6^!_P --7^*WC5;LZ7HML)KP6-N992I95&U<C/+#J0 ,DD $UQOQR^ GPA_
M;G^"&EZ3XQ_M*+3+]+?5]'OK4^1=6K/%E6PZL 2DA5E93U]0"/1R^AA_K%.K
MC8R]@Y6DX^6K2\[-7ZV/ SW&8]X+$87*9P^NJGS0C-Z:MI-KLVFD]KK70C^'
M_P 0/@'_ ,%!?V>KN>VTZXU'PSJ\C66K:7?;H)X9HV23RW,;95@?+<%6(P1S
MU%?)?B'_ (+):/\ "SQ^GPM^&GP/M+CP#X===*MWEU&1;J:VA_=!X\@JHVK\
MJMN) &6!)QY=X=_X*#Z]^Q5XMU'X%_LZ> M,D\':#XBN8[M_$(DEU#5Y4?RY
M9Y)49%B+",!55,*H7(8YSU/[4W[!'P4TCX-7O[=?A+Q;J]OX=UBQM-9A\%?8
M5+K)>R1[81<[_P!W&'F&<HQ ! ).*_3,#P]E>6XUT\SA)T*S_<1;;]Z5E[RB
M])M<MF]++5W1_/.<<><2<090L1P]5IQQN$C_ +9-1BKPA=WA*HGS4HRYW**U
M;:Y8M/74_:%_9+_9B_91\):7^W)X+EUG7]/U+5+*^\(>$+QD2S6>X4W,)FD4
M>88$5"WE\,=JJ7Y)KTC]ESXX_#G_ (*M>'M8^&'[3_P7TQ]0\,&.^L;K2IYX
MD\N0E"48/YD3 @ C>5<$<?+7-?L4?M4Z5^WO;:A^QI^T-\(M$;0XO#ZSZ+_8
MBSPK;1VQC1(_FD9E9592LBL/ND$'=7=?$W7OAA_P2CB\.>&_@'^SKJ&NGQUJ
MICU747U&1YG\HJ$A5]C[I#YK%(P%'#'DDD8XZ6,:>6XF,Y9A%WI3YTK0W^+F
MBD^523TNWUVMU9/3RJ'+G^7U*5/(IJV)I.E*3E5ORV=-PFVN>4'&TN6,=DM;
M_$NL_ME_'_X'_$[4/"_P7\13^#?#_A[7;F#3?"-G&#:Q(DS*5G1P3/(=OSO(
M2Q.<$# 'ZN_ +P'\,CX1T?XPZ#\&?#WAK7_$NA6U[JTFFZ+#!.))HDD>-G50
MQPQ[GMS6?XF_8M_98\>_$1/C!XL^".D7>OM(L\MU.CA99!@AY8@WER-ZEE)/
M?->I*JHH15  &  .E?-\2\1Y?F^'HQPE%TYI>^]/>VT;6LM;N\M;^K/T#P]X
M!SSA?'XJIFF*C7I2:]C&S:II7U2DK4W:T>6'NV25[)66BBBOC#];"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** # ZXHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BHX;NUN7DCM[F.1H7V2JC@E&P#@XZ'!!P?6N-T7XM:_JOQXUCX.7'
MPEUZTT[2]%AOH/&$\6-/O7<J#!&V.77<>^?D;(& 3K3HU*JDXKX5=ZI::+KO
MNM%J<U?%X?#N"F_CERJR;ULW;1.VB>KLO,[*6[M()8X)[F-'F8B%'< N0,D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYE=*RWV]ZA@L?G=.EQ5E#>,SG"RA3KPVIW2E%3M:#DU%*+Y)*+:<K6O?D?\
M@J;^SW\=/CUXK\'?$;]GWPQ<^*?!-UH*&Q@\-H)(XKB21I&N#&G:6-HOWF/X
M,$CC/UE^RY\&O$6F?LK^#/AQ^TGHECKFM:9I_P#IMOJ\,=X(&\QS%&2X8%HX
MF2/<,_=.">I[#X"?"BU^!GP:\-_".SU5[Y- TJ*T:\D3:9W RS[<G:"Q) R<
M# R<9KKJ_.\RXAKXG+J66P2]G1DW&:34FM;-ZZ73N^[M?8_>.'^!<'@,^Q&?
MUW+V^*IQ52DVI4XNT7)+35)QM&[=E=+1C+:VM[.W2TM+=(HHD"111H%5% P
M .  .U/HHKYK<_04DE9!1110,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\1_#SQ_\-M,TMM-THZE87VC&7RQ$)DB,,OF,V9#Y@(8%00C_ "C%>:?M#_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 29,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Crescent Biopharma, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 Fifth Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">430-5595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CBIO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cbio-20250729.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://crescentbiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cbio-20250729.htm">cbio-20250729.htm</File>
    <File>cbio-20250729.xsd</File>
    <File>cbio-20250729_lab.xml</File>
    <File>cbio-20250729_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cbio-20250729.htm": {
   "nsprefix": "cbio",
   "nsuri": "http://crescentbiopharma.com/20250729",
   "dts": {
    "inline": {
     "local": [
      "cbio-20250729.htm"
     ]
    },
    "schema": {
     "local": [
      "cbio-20250729.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cbio-20250729_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cbio-20250729_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://crescentbiopharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cbio-20250729.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cbio-20250729.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://crescentbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-25-036846-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-036846-xbrl.zip
M4$L#!!0    ( (@\_UJ!MY7WV10  $^%   1    8V)I;RTR,#(U,#<R.2YH
M=&WM/=MVVSB2[_T56/7.Q#Y'E$CJ+B>>XRA.6MWQ96WW]IQ]F0.1D(4)13(
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M:!"!!U#>@\?^*B,N\1H,!^1NW&H$;7\!3HM@N9AV,@9_&&)N';E+5#D:[W0
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MFN3?ALHY)^JW6]WDUUFV.4?_FN)_O"'UA=6'[\(-G)?#3Z='5W]>W/&#?'G
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M18<KMOM_LH;.L-OMY>@G4$L#!!0    ( (@\_UH(^%C:&@H  'U5   5
M8V)I;RTR,#(U,#<R.5]L86(N>&ULQ9QO;YM*%L;?]U.PV3>[TCTU,\P 4[6Y
MZN:V5]7FME&3ZE[M:F7-WP35,1$F3?+M=\!V8F*,F2&F;Q+''LYSGF-^/@=B
M>/OK_?4L^*&+19;/WQVAU^%1H.<R5]G\\MW1MXN/D![]>OSJU=N_ ?SUKZ^G
MP6^YO+W6\S(X*30OM0KNLO(J**]T\&=>?,]^\.!LQDN3%]< Q_5F)_G-0Y%=
M7I4!#C%=+UN_6KQ)$HE-&A.(C4B 4":!:6J <RV0B)E42/UR^08A)"C#$I2*
M0R!(19#&/ $5TY3'=EF<I'7063;__J;Z(?A"!];>?%'_^>[HJBQOWDPF=W=W
MK^]%,7N=%Y<3'(;19+WZ:+7\?FO]752O1HRQ2?WJX])%UK;0AD63O_XX/9=7
M^II#-E^4?"XK@47V9E$_>9I+7M95WYM7L'-%]1>LET'U%" ,$7I]OU!'QZ^"
M8%F.(I_IK]H$U>]O7S_ME&23:L5DKB^K]_9,%UFNSDM>E*=<Z)G-OHY6/MSH
M=T>+[/IFIM?/717:M(>=%44C:I4EJ[)$<97EWW>)30:D_T+YEMNYOD!RM=W/
M+Y5C5TT_OUBZ%_830A\^X0V9P2DO=Z@/<S76OOLH-3CUPV?\4KM%7O+9"+O%
MD\Q&RK/JB5/[:"53!>KX,*UU5A_=&ZGJ^U+/E5Y^6C9"!YEZ=V0?397.IN?Y
M+)-9:=OB'S:C(N.S:<)#Q2)*(-74=B2!!?"(,V T%(E,(Z,-FY:/>_14S^';
M^5J\5N@*?^3@JMQ!9Z$7^6TAEWW-2E8]?9G%\9-@L%9\.WG*S+D8LP-;G!W,
M72X;46=56\Z+YR9RN<?$TTZ^L"YJ!PLM7U_F/R9VPTDU^U0/H'I0[]L[PDVV
M2O^^6&?("[FG5JL5$YG;:>.FA$;93)%?][%2YGW>M66YK.!1D!=*%W9Z;$F^
ML=_\662EI>TDO[Z^G6?+\6<QY2G5+$8&5!(9(%(C8+'F@)C$8813;'#:EZ-6
MA0.CM-(,FJ+]:6JORGZ@!GMU8\K1IA-6G5:\R&J/.!I<G88V^>I>Z(Y8=50Q
M.[O*Y_KS[;70Q90IQ;B.*2 >ID"([5=<Z00DUI&*!(\8C?K2]3SX@<&JY8):
M+U@*]H=JJP[[>1KBS@TE!V-.&.URX$705K#1X-EE8Y.;G6O<D3G)?^CBO5B4
M!9?E5!)-DQ@QX*FRW2@R$E)#-:0QDJ%!.N68]^6E$?G L-1:P7_7:O_KCTK3
M_WY.O%VY0=+;D!,BK<E[\=&,-!H<K08VR6A?X([%^DS?X\'M;W8 G%*BE&4B
M!$EB"21A$?!8QD!U$AIC5!@CW!>/5H4#8_)X_G(I&EC5H)+MCTM[7?9C,]BM
M&S[.1ITPZC3CA5-[Q-&PZC2TB5?W0G?,S@I=#7_:9EB%O:A.1A1?C+$C"XUX
M3!15@ C&0+BQ72A-$E!:(4(039#4?5G;+7-@X*PPR WE8"D=U-K]J>LHTW[T
M7L:\&W]^OIT@W&_+B\2.L*/AN-_:)I,]5KN#^=Z&4E6XCS-^.:4FC+@@,:06
M.R!,"^!$:^ 4D5!1R@Q'?5EL1#XP?H]:0276G[>F^_V(>7MRHZJG'2>,6E/W
M(J<9:3186@UL\M&^P!V)#_,R*Q].;*""SSY9R.[_K1^F6 G&0L2!8QG9D3!F
M("+&0!F21EIQ%$O9%XU6A0,CLM0,5J)!K1I8V?ZPM-=E/S2#W;K!XVS4":-.
M,UXXM4<<#:M.0YMX=2\</!)^6BQN=;$Y\2 :$Z%##4*F HBRQ*6"Q<#22-1'
M9X@(S\%P2VSL\7"9P,M,B=N5<YX5!]5CX,3H4HHA@^-.CR\Q/FX'_UE#Y$Z;
M':/D[FU\N^<%O_^D;.3,K,[VK\Y/<\/B%%$-D>$*""((4F52B"AC.$0LQ%'H
MUD5W*(W33:UXT%1W/H7?7:^^W?4%JN#59=T+X-%M]Y@;T'5W11ZY^^XQN-V%
M]VW@B^V':UU<9O/+WXO\KKRR'Q$W?/XP%=BH-,0:<!QQ(#36P+1&@)A2/-*4
M2:S<H&W5&0?9M72PU Y6XJ[ ME>J+ZZ#_7O!ZFK= ]5.8P- ;8\[,J:=YK8A
M[5[NB^C';+;^9V_(,8DY0L (M5S:J@$SC(/2@L8JY'$DB1N73\''@;'2\^R8
M&W7H2YV?.R_4^ACSP&O;P0"F-H*-#-*VC6UZ6M;X(O-57V;5/PKGY6=^K:<B
MI5)K%@)'G #A(09A< S8X) CI65H'-M94V <=)XT@TK4%9]G->F+D+]3+XSZ
MFO1 J=W) )R>!1P9J78[VUCM6.>.UKF6MT75Y>[EE7WG=+T;(45))$(&#$4Q
MD"A5P&F*0".N:1)*FJC>_\MK$S@P6FO)8*WIB%9K3?:C-=2I&UJ.)MV^.-SA
MQ.^KPVT!Q_OR<(>=QM>'N]:YHW51\.K*M/.':Y'/IB1-<$(3!DDJ[92'I &6
MI@*8(IQR:5(<]?X"?B/R@6%::05+L?X0-=WOI\?;DQLV/>TXX=*:NA<GS4BC
M =)J8).,]@6^@]RGN<R+F[RH3WF<E[S4)_GMO"P>3G+;5TQ$I#0T <$$!B)%
M#&EH#X>$BNUQ4H2DQ(Z'0YUZXXQYC11^">HD;-6"52)!E8GK[-==QKZCX(L5
MQVLR'%07CW&QE]L!TV-W_)&'R5YFMV?+?IOYCYH(BXNLG.DIYI*$FF((I3!
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M?;V:M5:SLQI5@?YVXYN[-1Q/-\5J7<+VW#)!/)YZ'$K:P&:*F1;U/_<#9U_
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M>;/_RDS76+<*S5:AZ63]O[:LOXKUT2[H#9_#*8]>\81<S:_G>3JI5?2R3JZ
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M"?9GL!P;U;<?7"T]Z2!8,E\O&'E"ZTRC<4MQ)@TP*Y0V&TB/5B*3=GK^[%J
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M.<B.2]M^NM'7B/QA5N]:+C79_'-AYY:B1#%-PA+G=E8IVG,+(.B!QQ #U*:
M+M.,]?U S..42BP6H9^0!/DL4/5B@0%D3.B>IT"AH= <<.<FJ3!P#(8XO \$
M88*&KUI0O5,9W0AC892U03\&Z1[+A'JUT/IA<R:_I(X>32Y#>/I<O)->>5+
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M>$0N% Y+4[!_L9 B6YM3=B,+([X6. *F@C<&EVBMX4$_8TE[Q4 9*W("+IZ
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M"!4  &-B:6\M,C R-3 W,CDN>'-D4$L! A0#%     @ B#S_6@CX6-H:"@
M?54  !4              ( !G1<  &-B:6\M,C R-3 W,CE?;&%B+GAM;%!+
M 0(4 Q0    ( (@\_UKKL2VCK@8  .@P   5              "  >HA  !C
M8FEO+3(P,C4P-S(Y7W!R92YX;6Q02P$"% ,4    " "(//]:!N/^QS8S  #!
MDP$ '@              @ '+*   97AH:6)I="TQ,#%X97AE8W5T:79E<V5V
M97(N:'1M4$L! A0#%     @ B#S_6G]-=S3/%@  I[4  !<
M ( !/5P  '!R97-S<F5L96%S92UQ,C(P,C4N:'1M4$L%!@     &  8 E0$
' $%S      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>cbio-20250729_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cbio-20250729.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-07-29</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001253689</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-07-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Crescent Biopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36177</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">300 Fifth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">430-5595</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Ordinary Shares, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
